Experimental cell therapy for relapsed B-cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new cell therapy called CT1190B for people with certain types of B-cell lymphoma that have come back or not responded to at least two prior treatments. It aims to see if this therapy can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have a type of B-cell non-Hodgkin lymphoma that has returned or not responded to at least 2 prior treatments.
- You must have measurable disease (tumors that can be seen on scans).
- You must be well enough to carry out daily activities (ECOG score 0 or 1).
- You must have adequate organ function (kidneys, liver, blood counts) based on lab tests.
- You cannot have certain infections (like HIV, active hepatitis) or serious heart or lung conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug called CT1190B for people with a type of blood cancer (B-cell non-Hodgkin lymphoma) that has come back or stopped responding to at least two prior treatments. The study aims to see if the drug can help control the disease.
This study tests a new cancer treatment called CT1190B for people with certain types of B-cell lymphoma that have not responded to or came back after other treatments. The goal is to see if it can help shrink or control the lymphoma.
This trial tests a new treatment called CT1190B for people with B-cell non-Hodgkin lymphoma that has come back or stopped responding to at least two prior therapies. It aims to see if CT1190B can help when other treatments have failed or caused side effects.
This study tests a new therapy called CT1194C for people with B-cell non-Hodgkin lymphoma that has returned or stopped responding to at least two prior treatments. It aims to see if the therapy is safe and effective.
This trial tests a new type of CAR-T cell therapy designed to be stronger against B-cell lymphoma that has come back or not responded to previous treatments. The treatment uses your own immune cells, which are modified in a lab to better attack cancer cells.
This trial tests a new CAR-T treatment that targets three proteins on lymphoma cells (CD19, CD22, and BCMA). It is for people with certain types of B-cell lymphoma that have come back or are not responding to standard treatments.
Hear when a new B-Cell Non-Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.